Targets › FANCA
1 program from 1 company in 1 trial: 1 Phase 2; Hematology.
DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. (UniProt, O15360)
Open in Phaseline: the race on FANCA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rocket Pharmaceuticals | RP-L102 Lentiviral vector-mediated ex vivo gene transfer of FANCA gene into CD34+ hematopoietic st | FANCA | Phase 2 | Fanconi Anemia Complementation Group A | – |
Fanconi Anemia Complementation Group A (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.